Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy (Q46881099)

26 December 2017

title

Tau proteins expressions in advanced breast cancer and its significance in taxane-containing neoadjuvant chemotherapy (English)

1 reference

26 December 2017

author name string

Zhi-Hua Li

1

1 reference

26 December 2017

Qiu-Yun Xiong

2

1 reference

26 December 2017

Jian-Hong Tu

3

1 reference

26 December 2017

Yu Gong

4

1 reference

26 December 2017

Wei Qiu

5

1 reference

26 December 2017

Hui-Qin Zhang

6

1 reference

26 December 2017

Wen-Shong Wei

7

1 reference

26 December 2017

Yi-Feng Hou

8

1 reference

26 December 2017

Wei-Qi Cui

9

1 reference

26 December 2017

publication date

17 May 2013

1 reference

26 December 2017

published in

Medical Oncology

1 reference

26 December 2017

volume

30

1 reference

26 December 2017

issue

3

1 reference

26 December 2017

page(s)

591

1 reference

26 December 2017

https://scigraph.springernature.com/pub.10.1007/s12032-013-0591-y

exact match

0 references

cites work

Prevalence and correlates of major depressive disorder in breast cancer survivors in Shanghai, China.

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Cyclin G1 regulates the outcome of taxane-induced mitotic checkpoint arrest

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Adjuvant chemotherapy, with or without taxanes, in early or operable breast cancer: a meta-analysis of 19 randomized trials with 30698 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Markers predicting clinical benefit in breast cancer from microtubule-targeting agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

The role of Tau protein in resistance to paclitaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Adjuvant taxanes: more to the story

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Microtubule Associated Protein (MAP)-Tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Expression and silencing of the microtubule-associated protein Tau in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

The estrogen receptor influences microtubule-associated protein tau (MAPT) expression and the selective estrogen receptor inhibitor fulvestrant downregulates MAPT and increases the sensitivity to taxane in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumor res

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Evaluation of prognostic and predictive value of microtubule associated protein tau in two independent cohorts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

HER2-overexpressing breast cancer: time for the cure with less chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-013-0591-Y

Taxanes, microtubules and chemoresistant breast cancer.

21 January 2018

1 reference

12 December 2020

Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual

1 reference

12 December 2020

Association between HER-2/neu over-expression and clinico-pathologic parameters of breast cancer in northern Malaysia

1 reference

12 December 2020

Microtubule-associated protein-tau is a bifunctional predictor of endocrine sensitivity and chemotherapy resistance in estrogen receptor-positive breast cancer

1 reference

12 December 2020

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

1 reference

12 December 2020

The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile

1 reference

12 December 2020

10.1007/S12032-013-0591-Y

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

23681778

1 reference

26 December 2017